Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness

被引：26

作者：

Castro, Sara Guerreiro ^{[2
]}

Isenberg, David A. ^{[1
]}

机构：

[1] UCL, Ctr Rheumatol, Room 424,4th Floor Rayne Bldg,5 Univ St, London WC1E 6JF, England

[2] Hosp Curry Cabral, Ctr Hosp Lisboa Cent, Internal Med Dept 7 2, Autoimmune Dis Unit, Lisbon, Portugal

来源：

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE | 2017年 / 9卷 / 03期

关键词：

belimumab; biologic therapy; immunosuppressive agents; systemic lupus erythematosus; B-LYMPHOCYTE STIMULATOR; DISEASE-ACTIVITY; MONOCLONAL-ANTIBODY; SAFETY; INHIBITOR;

D O I：

10.1177/1759720X17690474

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Systemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with multiple presentations, whose management presents many challenges. Many disease modifying or immunosuppressive drugs have been used with limited success, especially in patients with more severe disease activity. Belimumab is the first drug to be approved specifically for the treatment of SLE in more than 50 years. By blocking the B-cell activating factor, it interferes in B-cell differentiation and survival. Here we consider the results of the clinical trials that led to its approval, as well as the post-hoc analyses, follow-up studies and the current trials.

引用

页码：75 / 85

页数：11

共 35 条

[1]

Acosta-Mérida A, 2013, CLIN EXP RHEUMATOL, V31, P656

[2]

Arthritis Research UK, 2015, EV POT BEL TREAT PAT

[3] Post-marketing Experiences with Belimumab in the Treatment of SLE Patients [J].

Askanase, Anca D. ;

Yazdany, Jinoos ;

Molta, Charles T. .

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2014, 40 (03) :507-+

[4] Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator [J].

Baker, KP ;

Edwards, BM ;

Main, SH ;

Choi, GH ;

Wager, RE ;

Halpern, WG ;

Lappin, PB ;

Riccobene, T ;

Abramian, D ;

Sekut, L ;

Sturm, B ;

Poortman, C ;

Minter, RR ;

Dobson, CL ;

Williams, E ;

Carmen, S ;

Smith, R ;

Roschke, V ;

Hilbert, DM ;

Vaughan, TJ ;

Albert, VR .

ARTHRITIS AND RHEUMATISM, 2003, 48 (11) :3253-3265

[5] Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care [J].

Bruce, I. N. ;

Urowitz, M. ;

van Vollenhoven, R. ;

Aranow, C. ;

Fettiplace, J. ;

Oldham, M. ;

Wilson, B. ;

Molta, C. ;

Roth, D. ;

Gordon, D. .

LUPUS, 2016, 25 (07) :699-709

[6] Elevated Serum BAFF Levels Are Associated With Rising Anti-Double-Stranded DNA Antibody Levels and Disease Flare Following B Cell Depletion Therapy in Systemic Lupus Erythematosus [J].

Carter, Lucy M. ;

Isenberg, David A. ;

Ehrenstein, Michael R. .

ARTHRITIS AND RHEUMATISM, 2013, 65 (10) :2672-2679

[7] Effect of Belimumab on Vaccine Antigen Antibodies to Influenza, Pneumococcal, and Tetanus Vaccines in Patients with Systemic Lupus Erythematosus in the BLISS-76 Trial [J].

Chatham, W. Winn ;

Wallace, Daniel J. ;

Stohl, William ;

Latinis, Kevin M. ;

Manzi, Susan ;

McCune, W. Joseph ;

Tegzova, Dana ;

McKay, James D. ;

Avila-Armengol, Hilario E. ;

Utset, Tammy O. ;

Zhong, Z. John ;

Hough, Douglas R. ;

Freimuth, William W. ;

Thi-Sau Migone .

JOURNAL OF RHEUMATOLOGY, 2012, 39 (08) :1632-1640

[8] Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA [J].

Collins, C. E. ;

Dall'Era, M. ;

Kan, H. ;

Macahilig, C. ;

Molta, C. ;

Koscielny, V. ;

Chang, D. J. .

LUPUS SCIENCE & MEDICINE, 2016, 3 (01)

[9]

Díaz-Cerezo Silvia, 2015, Farm Hosp., V39, P161

[10] Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response [J].

Do, RKG ;

Hatada, E ;

Lee, H ;

Tourigny, MR ;

Hilbert, D ;

Chen-Kiang, S .

JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (07) :953-964

← 1 2 3 4 →